Pluristem Therapeutics Inc. NASDAQ:PSTI Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a

Location: Matam Advanced Technology Park, Haifa, 3508409, Israel | Website: www.pluristem.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing